This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Cryoport, Inc. (OTC BB: CYRX) ("the Company"), the leading, global provider of advanced cryogenic logistics solutions, today announced the appointment of Ramkumar Mandalam, Ph.D., to its Board of Directors. Additionally, he has been appointed to serve as a member of the Compensation and Nominating and Governance Committees. Following Dr. Mandalam's appointment, Cryoport's Board of Directors will have a total of five members, including four independent members.
"The need for an effective and efficient cryogenic transportation is critical to preserve the potency and viability of sensitive biological cellular materials that are being developed in the growing fields of Regenerative Medicine and Immunotherapy," stated Dr. Mandalam. He continued, "Cryoport provides unique shipping solutions in a comprehensive, easy-to-use, economic, and reliable manner while addressing the time and temperature sensitivities of these materials. I am excited to join Cryoport's Board and look forward to contributing to its continued growth. I am eager to work with the Company's experienced management team and other board members as we look to further expand the market for cryogenic logistics for biologic materials."
Jerrell Shelton, Chief Executive Officer of Cryoport, stated, "We welcome Dr. Mandalam to our Board. He brings invaluable industry expertise within the life sciences. His extensive insights will allow us to better navigate our markets from our clients' perspectives. We will benefit tremendously from his expertise as the already large and growing cryogenic logistics market becomes further enhanced by rapidly developing autologous and allogeneic therapies."
"I am delighted to welcome Dr. Mandalam to our Board," commented Richard Rathmann, Chairman of the Board of Cryoport. "Dr. Mandalam complements the Board with his experience and success in leading the development of complex biological products. He will be a great asset to Cryoport as we strengthen our position as the premier global logistics provider in the cold chain."
Dr. Mandalam joins Cryoport's Board with twenty years of experience in the development of biologics. He is currently the President and Chief Executive Officer of Cellerant Therapeutics, Inc., a clinical stage biotechnology company developing cellular and antibody therapies for the treatment of hematological malignancies and blood related disorders. Previously, Dr. Mandalam served as Executive Director of Product Development at Geron Corporation, where he managed the development and manufacturing of cell based therapies for treatment of degenerative diseases and cancer. Dr. Mandalam has also held positions of increasing responsibility at Aastrom Biosciences, most recently as Director of Developmental Research. Dr. Mandalam received his Ph.D. in Chemical Engineering from the University of Michigan. He is the author or co-author of several publications, patent applications, and abstracts.
